TAE Life Sciences Partners with Biddle Sawyer for Cancer Treatment Drug

TAE Life Sciences has  announced a landmark agreement with Biddle Sawyer to serve as the exclusive supplier of TC220, a novel boronated amino aci...

August 16, 2023 | Wednesday | News
Propanc Targets First Human Study Site at Peter Mac Cancer Center, Australia

The Peter Mac Cancer Center is a world leading cancer research, education and treatment center and Australia’s only public health service dedicated t...

August 16, 2023 | Wednesday | News
Gilead, Tentarix Partner to Develop Therapies for Cancer and Inflammation

– Collaboration Combines Gilead’s Oncology and Inflammation Expertise and Tentarix’s Tentacles™ Platform – – Gilead Re...

August 16, 2023 | Wednesday | News
Zetagen Raises $9.79M Series B for ZetaMet™ and ZetaMAST™ in Metastatic Lesion Treatment

ZetaMet™ is a first-of-its kind molecular pathway designed to suspend cancer, inhibit pain, and regenerate bone. ZetaMet™ is presently i...

August 14, 2023 | Monday | News
Oncolytics Biotech® Raises $15M to Advance Cancer Clinical Programs

Leede Jones Gable Inc. acted as underwriter and bookrunner (the "Underwriter") in accordance with the terms of an underwriting agreement between the Compan...

August 09, 2023 | Wednesday | News
Astellas Invests in Poseida Therapeutics to Redefine Cancer Cell Therapy

Poseida is a clinical-stage biotechnology company dedicated to advancing a new class of cancer cell therapy and gene therapy products using genetic enginee...

August 08, 2023 | Tuesday | News
Guardant Settles Litigation with Illumina, Forges New Partnership for Cancer Research

he three-year agreement includes a joint request to dismiss with prejudice the pending litigation between the companies, including any allegations related ...

August 02, 2023 | Wednesday | News
Australia: First Patient Dosed in Chemotherapy-Free Soft Tissue Sarcoma Trial.

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immu...

July 31, 2023 | Monday | News
China's SunHo Initiates Phase I/II Trial for First-in-Class Immunocytokine IBB0979

"We are excited for achieving this important milestone, which also marked the first step to what we hope will ultimately allow us to bring an innovative ca...

July 24, 2023 | Monday | News
Menarini Group Receives Positive CHMP Opinion for ORSERDU® in ER+ Metastatic Breast Cancer

Each year in Europe more than 550,000 patients are diagnosed with breast cancer, of whom 70% have estrogen receptor (ER)-positive disease¹; more tha...

July 24, 2023 | Monday | News
NANOBIOTIX Initiates Phase 1/2 Study of NBTXR3 Plus Anti-PD-1 in Advanced Cancers

Announced that the first patient has been injected in a Phase 1/2 study evaluating NBTXR3 activated by radiation therapy in combination with anti-PD-1/L-1 ...

July 20, 2023 | Thursday | News
HUTCHMED's Fruquintinib Combo Receives Breakthrough Designation in China for Advanced Endometrial Cancer, Enrollment Complete

It is a multi-center, open-label clinical study to evaluate the efficacy and safety of fruquintinib in combination with sintilimab. Entry criteria include ...

July 20, 2023 | Thursday | News
Junshi Biosciences' Toripalimab Accepted for First-line Treatment of Extensive-stage Small Cell Lung Cancer

According to data released by GLOBOCAN 2020, lung cancer is currently the most prevalent malignant tumor with the highest mortality rate in China. Small ce...

July 20, 2023 | Thursday | News
Massive Bio and CureMatch Partner to Revolutionize Cancer Treatment with AI and Clinical Trial Accessibility.

Massive Bio, an AI-powered platform connecting patients with clinical trials and CureMatch, a healthcare technology company leveraging Knowledge Representa...

July 19, 2023 | Wednesday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close